- AstraZeneca said its type-2 diabetes drug was approved by US regulators to reduce the risk of hospitalisation for heart failure in adults with the condition and established cardiovascular disease.

The approval came on the back of results from a Declare-Timi 58 cardiovascular outcomes trial (CVOT), to evaluate type-2 diabetes patients with multiple cardiovascular risk factors or established cardiovascular disease.

'This is promising news for the 30m people living with type-2 diabetes in the US, as heart failure is one of the earliest cardiovascular complications for them, before heart attack or stroke,' said Ruud Dobber, executive vice president of the company's biopharmaceuticals business unit.

'Farxiga now offers the opportunity for physicians to act sooner and reduce the risk of hospitalisation for heart failure.'

Story provided by